Cardiol Therapeutics Inc.
TSX:CRDL.TODrug Manufacturers - Specialty & Generic
+$0.00 today
- Market cap
- $164.10M
- Beta
- 0.48
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.08M
Average 0.12M
CRDL.TO Income Before Tax
Profit after all operating and non-operating items but before income tax.
Cardiol Therapeutics Inc.TSX: CRDL.TO
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax remains negative
Q1 FY2026 income before tax was -CA$10.82M, compared with -CA$8.29M a year earlier. Trailing-twelve-month income before tax was -CA$36.35M.
Context
- Income before tax grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly income before tax holds near -CA$10.82M or moves back toward the trailing-twelve-month quarterly average of -CA$9.09M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
CAD · from the income statement
- Latest · FY2025
- (33.82M) CAD
- Year-over-year change
- +7.8%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.82M) | +7.8% |
| FY2024 | 2024-12-31 | (36.68M) | -30.4% |
| FY2023 | 2023-12-31 | (28.13M) | +9.1% |
| FY2022 | 2022-12-31 | (30.93M) | +2.2% |
| FY2021 | 2021-12-31 | (31.64M) | — |
Income Before Tax vs competitors
How CRDL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1.6% is the lowest of 2, against a peer median of +23.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$10.7M USD | +23.0% | — | 19.2% | |
MSCL.TOSatellos Bioscience Inc. | LTM Mar 2026 | -$26.83M USD | — | — | — |
| LTM Mar 2026 | -CA$36.35M CAD | -1.6% | — | — | |
| Peer median (excluding CRDL.TO) | — | +23.0% | — | 19.2% | |
Competitors are the stored peer set for CRDL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 78.76K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 220.42K | 219.91K | 248.36K | 373.11K | 101.98K |
| Gross Profit | 78.76K | (219.91K) | (248.36K) | (373.11K) | (101.98K) |
| Gross Margin | 100.0% | — | — | — | — |
| Research & Development | 10.87M | 18.96M | 14.22M | 14.01M | 14.02M |
| Selling, General & Admin | 27.87M | 22.37M | 15.56M | 25.89M | 20.2M |
| Operating Expenses | 38.74M | 41.34M | 29.54M | 39.9M | 34.32M |
| Depreciation & Amortization | 220.42K | 219.91K | 248.36K | 373.11K | 101.98K |
| EBITDA | (38.44M) | (30.71M) | (27.88M) | (36.3M) | (34.21M) |
| EBITDA Margin | -48812.1% | — | — | — | — |
| Operating Income | (45.47M) | (50.34M) | (29.79M) | (40.28M) | (34.32M) |
| Operating Margin | -57736.3% | — | — | — | — |
| Interest Income | 106K | 1.24M | 2.04M | 1.19M | 726.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7.03M | 10.41M | 1.66M | 3.6M | 497.42K |
| Income Before Tax | (31.64M) | (30.93M) | (28.13M) | (36.68M) | (33.82M) |
| Pre-Tax Margin | -40170.4% | — | — | — | — |
| Income Tax Expense | (6.91M) | (19.41M) | 0 | 0 | 0 |
| Net Income | (24.72M) | (11.52M) | (28.13M) | (36.68M) | (33.82M) |
| Net Margin | -31391.5% | — | — | — | — |
| EPS (Basic) | (0.57) | (0.18) | (0.44) | (0.51) | (0.39) |
| EPS (Diluted) | (0.57) | (0.18) | (0.44) | (0.51) | (0.39) |
| Weighted Avg Shares | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
| Weighted Avg Shares (Diluted) | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
Cardiol Therapeutics Inc.
TSX:CRDL.TO
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.